Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicadex is a handheld, medically oriented electronic nicotine delivery system being developed as a nicotine replacement therapy for smoking cessation and harm reduction. It functions as an electronic inhaler that vaporizes a pharmaceutical‑grade nicotine solution, allowing users to inhale purified nicotine without exposure to the combustion products and toxic gases associated with conventional cigarettes.[5][6] By delivering controlled doses of nicotine via inhalation, Nicadex aims to alleviate withdrawal symptoms and cravings in smokers seeking to quit, while potentially reducing tobacco‑related harm relative to smoking.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nicadex.